

## Neuropathic Pain Market Size Estimated to Cross a Worth of US\$ 12.5 Billion at a CAGR of 5.2% by 2032 | insightSLICE

The market for neuropathic pain is anticipated to rise as a result of rising R&D spending by different industry participants to develop cutting-edge goods.

# CinsightSLICE® Partnering Intelligence

SANTA ROSA, CALIFORNIA, UNITED STATES, June 9, 2023 /EINPresswire.com/ -- Neuropathic insightSLICE

pain, which affects 7–10% of the population as a whole, is brought on by an injury or illness of the somatosensory nervous system, which includes neurons in the brain and peripheral axons (A, AB, and C fibers). Numerous reasons for neuropathic pain have been discovered or identified,

### ٢

The neuropathy-pain industry in North America is therefore anticipated to develop throughout the course of the forecast period as a result of the aforementioned factors." *insightSLICE*  and its prevalence is predicted to rise as the world's population ages, the prevalence of Type 2 diabetes rises, and post-chemotherapy cancer outcomes improve.

DDD D DDDDD DDDDDD: https://www.insightslice.com/request-sample/1120

Although there are several indications of nerve pain, diabetic neuropathy is among the most common ones. Diabetic neuropathy can cause discomfort and numbness in the hands, feet, and legs. It might consequently result in

issues with the coronary arteries, blood vessels, gastrointestinal tract, and urine system.

The <u>DODE DODE DODE DODE</u> was estimated to be US\$ 7.5 billion in 2022 and is expected to reach US\$ 12.5 billion by 2032 at a CAGR of 5.2%. The market for neuropathic pain is anticipated to rise as a result of rising R&D spending by different industry participants to develop cutting-edge goods. Over the past several decades, there has been a growth in the number of treatment facilities worldwide due to the increased prevalence of disorders linked to pain.

Developing countries like China and India are improving their medical facilities as a result of increasing expenditure on healthcare and income per capita. As a result, it is projected that a surge in the amount of pain management facilities and an expansion in R&D spending will contribute to the growth of the neuropathic pain market.



Neuropathic Pain Market- insightSLICE

The usage of products is restricted by

limitations connected to medical equipment, which is anticipated to impede market growth for neuropathic pain. Growing older populations and an elevated risk of neuropathic pain in many nations will open up opportunities for the market for neuropathic pain to expand.

The use of traditional treatments in developing nations due to low health spending and a disrupted distribution system is anticipated to be a barrier to the market's expansion for treatments for neuropathic pain. Nevertheless, the accessibility of an extensive range of approved medications and the adoption of new, helpful guidelines for the management of neuropathic pain have greatly expanded the market's potential.

#### 

The neuropathic pain market is divided into many categories based on the kind of discomfort, the product type, the process, the technology, the technique, the mode of purchase, the diagnosis, the end consumer, and the sales channel. The neuropathic pain market is divided into three types of products: transcutaneous electric nerve stimulation (TENS), exterior peripheral stimulation of neurons, and spinal cord stimulator (SCS) devices. The neuropathic pain market is divided into chargeable and non-rechargeable segments based on the kind of product. The neuropathic pain market is divided between invasive and non-invasive procedures based on technique.

The neuropathic pain market is divided into indications for peripheral neuropathy brought on by radiation therapy, diabetic neuropathy, spinal canal stenosis, and others. Due to shifting habits of living that are leading to an increase in diabetes patients at younger ages, the diabetic neuropathy category is expected to take over the market in the coming years. The neuropathic pain market is divided into clinics, hospitals, home medical care, outpatient surgical centers, and other entities based on the end customer.

The transcutaneous electromagnetic nerve stimulation, magnetic transcranial stimulation, and pulmonary electric stimulation segments of the neuropathic pain treatment market are divided as per their technology. Transcutaneous electrical nerve stimulation (TENS) is a non-invasive, affordable, and autonomous method of pain relief, and as technology advances, the market for such devices is growing.

In 2021, it is anticipated that this segment will experience substantial expansion. The neuropathic pain market is divided into segments based on the kind of pain: discomfort in the feet, coccydynia, trigeminal neuralgia (TN), post-surgical neuralgia (PHN), phantom limb neuropathy, neuropathy of the legs, and adhesion neuropathy.

#### 

In 2021, the North American market for neuropathic pain was valued at \$1.06 billion, and over the course of the study time frame, it is anticipated to increase at a strong CAGR of 43.5 percent. The United States of America (USA) has the greatest market share based on revenue and sales within the North American area. Over the course of the projection period, it is anticipated that the existence of prominent market participants, sizable biopharmaceutical and biotechnology sectors, and higher expenditures in the nation for the implementation of cutting-edge technologies will fuel regional market expansion.

The increasing number of senior people in the area, which results in a number of illnesses and maladies, is to blame for this rise. Additionally promoting the market's expansion in the region is a number of industry stakeholders' efforts. The neuropathy-pain industry in North America is therefore anticipated to develop throughout the course of the forecast period as a result of the aforementioned factors.

#### 

The market for drugs to treat neuropathic pain is dominated by companies like Abbott, Pfizer, Astellas, Sanofi, Johnson & Johnson, Eli Lilly, GSK, and AstraZeneca, among others. Leading pharmaceutical firms are focusing on developing improved pain management techniques. However, only a small number of manufacturers are dedicated to developing neuropathyfighting drugs with minor adverse reactions.

#### 

- Tricyclic Antidepressants
- Opioids

- Capsaicin Cream
- Steroids
- Others

#### 

- Diabetic Neuropathy
- Spinal Stenosis
- Chemotherapy-induced Peripheral Neuropathy

#### 

- Retail Pharmacies
- Hospital Pharmacies
- Online Pharmacies
- Others

#### 

- North America
- > United States
- > Canada
- > Rest of North America
- Europe
- > Germany
- > United Kingdom
- > Italy
- > France
- > Spain
- > Rest of Europe
- Asia Pacific
- > Japan
- > India
- > China
- > Australia
- > South Korea
- > Rest of Asia Pacific
- Middle East & Africa
- > UAE
- > Saudi Arabia

> South Africa

- > Rest of the Middle East & Africa
- South America
- > Brazil
- > Rest of South America

#### 0000000:

insightSLICE is a market intelligence and strategy consulting company. The company provides tailor-made and off-the-shelf market research studies. The prime focus of the company is on strategy consulting to provide end-to-end solutions.

#### 0000000000:

Alex insightSLICE (Same Page Management Consulting Pvt. Ltd.) +1 707-736-6633 alex@insightslice.com Visit us on social media: Twitter LinkedIn Other

This press release can be viewed online at: https://www.einpresswire.com/article/638569721

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire<sup>™</sup>, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information. © 1995-2024 Newsmatics Inc. All Right Reserved.